On January 2, 2024, Director William Rastetter executed a sale of 11,044 shares of Neurocrine Biosciences Inc (NBIX, Financial), according to a recent SEC Filing. Over the past year, the insider has sold a total of 22,281 shares and has not made any purchases of the company's stock.
Neurocrine Biosciences Inc is a biopharmaceutical company focused on developing treatments for neurological and endocrine-related diseases and disorders. The company's portfolio includes products and candidates for a range of conditions, with an emphasis on addressing unmet medical needs in the areas of neurology and endocrinology.
The insider transaction history for Neurocrine Biosciences Inc shows a pattern of insider sales, with 54 insider sells recorded over the past year and no insider buys during the same period.
On the valuation front, Neurocrine Biosciences Inc's shares were trading at $131.47 on the day of the insider's recent transaction, giving the company a market capitalization of $13.227 billion. The price-earnings ratio stands at 71.82, which is above the industry median of 24.355 but below the company's historical median price-earnings ratio.
According to the GF Value, with a share price of $131.47 and a GuruFocus Value of $149.19, Neurocrine Biosciences Inc has a price-to-GF-Value ratio of 0.88, indicating that the stock is considered Modestly Undervalued.
The GF Value is determined by considering historical trading multiples, a GuruFocus adjustment factor based on past returns and growth, and future business performance estimates provided by Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
